Therapeutic Drug Monitoring in Child and Adolescent Psychiatry

• Status: Completed
• Trial end date: 2019-03-05
• Target enrollment: 0
• Participant gender: All

Summary

The investigators aim to analyse in adolescents with mental illness effectiveness, side effects, and serum level concentrations of antipsychotics (olanzapine and aripiprazole), antidepressants (Duloxetine, Atomoxetine) by means of "Therapeutic Drug Monitoring" (TDM) in order to optimize dosage - effect relations and minimize unwanted side effects.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of Vienna
• Treatments: Aripiprazole; Atomoxetine Hydrochloride; Duloxetine Hydrochloride; Olanzapine

Criteria

Inclusion Criteria:

• appropriate diagnosis and severity of the disorder of interest

• age range 10-19

Exclusion Criteria:

• below 10 yrs of age

• no written informed consent possible due to intelligence or no willingness by parents to include minor